NCT00191568已完成2 期
A Phase II Trial of Adjuvant Treatment With Gemcitabine and Oxaliplatin Followed by Concomitant Gemcitabine and Radiation Therapy in Patients With Resected Pancreatic Adenocarcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 7
- 主要终点
- To evaluate recurrence free one year survival, time to disease progression and local recurrence rate, analyzed at the end of the study
研究概览
简要总结
A non-randomized phase II study to determine the efficacy and safety of the combination of Gemcitabine and Oxaliplatin followed by Gemcitabine and radiotherapy in patients with surgically resected pancreatic cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed adenocarcinoma of the pancreas
- •Patient have undergone a potentially curative resection
- •No previous irradiation to the planned field
- •Negative pregnancy test for child bearing women
排除标准
- •Non-adenocarcinoma pancreatic cancer
- •Treatment with any drug within the last 30 days that has not received regulatory approval.
- •Serious systemic disorder
- •Metastatic disease
- •Pregnancy, breast feeding
结局指标
主要结局
To evaluate recurrence free one year survival, time to disease progression and local recurrence rate, analyzed at the end of the study
次要结局
- To assess overall survival at the end of the 24 months follow up period;To assess acute and late toxicity (every month for the first 3 months and then every three months for 24 months after treatment discontinuation)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical ResectionCholangiocarcinomaNCT01043172National Cancer Center, Korea72
招募中
2 期
A phase II clinical trial of neoadjuvant gemcitabine and S-1 with concurrent radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinomaresectable and borderline resectable (BR-PV) pancreatic cancerJPRN-UMIN000053195Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University64
招募中
2 期
A phase II clinical trial of neoadjuvant gemcitabine and S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinomaresectable and borderline resectable (BR-PV) pancreatic cancerJPRN-UMIN000038585Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University54
招募中
2 期
Randomized phase II trial of neoadjuvant Gemcitabine/S-1 based chemoradiotherapy for potentially resectable pancreatic ductal adenocarcinomainvasive pancreatic ductal adenocarcinomainvasive pancreatic ductal adenocarcinoma, potentially resectable pancreatic cancerJPRN-jRCTs041200079Mizuno Shugo70
已完成
2 期
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesAdult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaIntraocular LymphomaNodal Marginal Zone B-cell LymphomaAnaplastic Large Cell LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaSmall Intestine LymphomaSplenic Marginal Zone LymphomaTesticular LymphomaWaldenstrom MacroglobulinemiaNCT00072514Fred Hutchinson Cancer Center55